HEIDELBERG PHARMA AG O.N./ DE000A11QVV0 /
| 15/11/2024 21:45:05 | Diferencia +0.020 | Volumen | Bid22:00:00 | Ask22:00:00 | Capitalización de mecado | Dividendo A. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 2.290EUR | +0.88% | 0 Volumen de negocios: 0.000 |
-Volumen de oferta: - | -Tamaño/ Volumen/ Formato de Ask: - | 77.92 millonesEUR | 0.00% | - |
GlobeNewswire
16/11/2017
Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%
GlobeNewswire
12/11/2007
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
12/11/2007
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
05/02/2007
Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis
GlobeNewswire
09/10/2006
Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients
